XML 31 R22.htm IDEA: XBRL DOCUMENT v3.22.2

Balance Sheet Components (Tables)

6 Months Ended

Jun. 30, 2022

Organization, Consolidation and Presentation of Financial Statements [Abstract]

Schedule of Cash and Cash Equivalents

Cash and cash equivalents consisted of the following (in thousands):

		June 30, 2022				December 31, 2021
Cash		$	128,152			$	111,422
Commercial paper			5,483				1,000
Money market funds			34,123				58,801
Total cash and cash equivalents		$	167,758			$	171,223

Summary of Amortized Cost, Gross Unrealized Holding Gains or Losses, and Fair Value of Investments

The Company’s investments consist of available-for-sale debt investments and marketable equity investments. The amortized cost, gross unrealized holding gains or losses, and fair value of the Company’s investments by major investments type are summarized in the tables below (in thousands):

		June 30, 2022
		Amortized Cost				Gross Unrealized Holding Gains				Gross Unrealized Holding Losses				Fair Value
Corporate bonds		$	127,387			$	—			$	(1,896	)		$	125,491
Commercial paper			49,824				—				—				49,824
U.S. government bonds			118,142				—				(1,787	)			116,355
Agency bonds			15,235				—				(305	)			14,930
Asset-backed securities			4,751				—				(10	)			4,741
Foreign government bonds			5,032				—				(78	)			4,954
Total investments		$	320,371			$	—			$	(4,076	)		$	316,295
		December 31, 2021
		Amortized Cost				Gross Unrealized Holding Gains				Gross Unrealized Holding Losses				Fair Value
Corporate bonds		$	183,136			$	2			$	(492	)		$	182,646
Commercial paper			68,079				—				—				68,079
U.S. government bonds			91,840				—				(318	)			91,522
Agency bonds			23,339				—				(64	)			23,275
Asset-backed securities			27,105				—				(18	)			27,087
Foreign government bonds			9,165				—				(11	)			9,154
Total investments		$	402,664			$	2			$	(903	)		$	401,763

Schedule of Inventory

Inventories consisted of the following (in thousands):

		June 30, 2022				December 31, 2021
Raw materials		$	1,220			$	1,363
Work-in-progress			34,488				21,499
Finished goods			5,191				8,153
Total inventories		$	40,899			$	31,015

Schedule of Accrued and Other Current Liabilities

Accrued and other current liabilities consisted of the following (in thousands):

		June 30, 2022				December 31, 2021
Preclinical and clinical trial accruals		$	66,553			$	56,283
API and bulk drug product price true-up			54,443				—
Acquired in-process research and development asset			—				35,000
Payroll and related accruals			13,480				20,909
Accrued co-promotion expenses - current			32,352				25,746
Contract liabilities to pharmaceutical distributors			1,402				3,176
Roxadustat profit share to AstraZeneca			7,497				7,895
Property taxes and other taxes			5,449				12,610
Professional services			4,929				6,074
Other			6,994				4,906
Total accrued and other current liabilities		$	193,099			$	172,599

X

- References

No definition available.

+ Details

Name:	us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract
Namespace Prefix:	us-gaap_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration

X

- Definition

Tabular disclosure of the components of accrued liabilities.

+ References

No definition available.

+ Details

Name:	us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock
Namespace Prefix:	us-gaap_
Data Type:	dtr-types:textBlockItemType
Balance Type:	na
Period Type:	duration

X

- Definition

Tabular disclosure of the reconciliation of available-for-sale securities from cost basis to fair value.

+ References

No definition available.

+ Details

Name:	us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock
Namespace Prefix:	us-gaap_
Data Type:	dtr-types:textBlockItemType
Balance Type:	na
Period Type:	duration

X

- Definition

Tabular disclosure of the components of cash and cash equivalents.

+ References

No definition available.

+ Details

Name:	us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock
Namespace Prefix:	us-gaap_
Data Type:	dtr-types:textBlockItemType
Balance Type:	na
Period Type:	duration

X

- Definition

Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(6)(c))
-URI https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(6)(b))
-URI https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(6)(a))
-URI https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section 50
-Paragraph 1
-URI https://asc.fasb.org/extlink&oid=6361739&loc=d3e7789-107766

+ Details

Name:	us-gaap_ScheduleOfInventoryCurrentTableTextBlock
Namespace Prefix:	us-gaap_
Data Type:	dtr-types:textBlockItemType
Balance Type:	na
Period Type:	duration